Tune In, Turn On and Cheer Up: Swiss Psychiatrist Fights Fear with LSD
A Swiss psychiatrist is treating severely ill patients with LSD to alleviate their fear of pain and death. Other psychedelic drugs are being tested on patients in the United States, Britain and Israel. Are psychotropic substances about to make a comeback in therapy?
Nothing's happening, Udo Schulz thought to himself with quiet regret. I must have been given the placebo. He was lying on a mattress in a brightly lit room, waiting for the first real drug experience of his life.
The wall of the treatment room was decorated with a red tapestry, a gong, a drum and a portrait of a smiling Buddha. Peter Gasser, a psychiatrist, and fellow therapist Barbara Speich crouched next to the patient on thin foam rubber mats.
They sat there for at least half an hour, waiting. "Then I finally sensed that something was changing in my psyche," recalls Schulz. "Wow, it was fantastic!"
Transported to a Different World
Swiss chemist Albert Hofmann synthesized, ingested and discovered the effects of LSD in a laboratory at the pharmaceutical company Sandoz in Basel on April 19, 1943. Hofmann had originally intended to develop a circulatory stimulant derived from ergot, a fungus. Instead, he synthesized a highly potent hallucinogen. A single gram of LSD is sufficient to get 20,000 people high for hours.
Of course, the young scientist couldn't have known this on the day of his discovery. As a result, the first LSD trip in history began with a drastic overdose, when Hofmann swallowed 0.25 milligrams of the substance. "I was filled with an overwhelming fear that I would go crazy," he later wrote, describing his experience. "I was transported to a different world, a different time." Hours passed before he gradually became calm again. "Now I gradually began to enjoy the unimaginable play of colors and shapes," he wrote. The next day, he wrote, he was filled with "a feeling of well-being and new life."
Hofmann couldn't have dreamed that LSD would soon become the catalyst of a mass movement, glorified by artists like the Beatles, the Doors, Pink Floyd, the actor Cary Grant and the author Aldous Huxley. Little did he suspect that the CIA would secretly use it in interrogations or that the hallucinogen would send millions of people on spiritual and creative adventures but also drive some to madness and suicide. Nevertheless, he was convinced from the start that LSD had to be suitable for providing "mental relaxation."
Many psychiatrists shared Hofmann's hope that the substance he had discovered could help them gain insights into suppressed memories and trauma. Until the 1970s, LSD was frequently used to treat depression, anxiety and addiction and, less commonly, migraines, arthritis, paralysis and skin complaints. Thousands of scientific studies were published during that time, most of which were of dubious quality. A famous case was that of Auschwitz survivor Yehiel De-Nur, who, in six LSD sessions in 1976, relived his memories of the death camp. He later published a poetic and deeply disturbing book entitled "Shivitti: A Vision" about the experience.
Albert Hofmann's Problem Child
LSD discoverer Albert Hofmann died at the age of 102 on April 29, 2008 -- just two weeks before Udo Schulz was to travel by train from Murnau in Bavaria to Solothurn to take LSD as the first subject in the study. Schulz hoped that the substance could help him face the fears that had tormented him ever since he was diagnosed with cancer.
Hofmann had always warned against the dangers posed by his "problem child," and yet he continued to believe in the drug's healing powers up until his death. For the old man, the fact that research into the medical uses of LSD was now continuing after a 35-year hiatus represented the fulfillment of his "greatest wish in life."
Study director Gasser carries a heavy burden of responsibility. It isn't just a question of doing justice to Albert Hofmann's legacy. Many scientists from the United States and Europe, who have been fighting for years to be allowed to continue research into LSD and other psychedelic substances, are now pinning their hopes on the Solothurn-based psychiatrist.
"I would welcome it if it were easier to use psychoactive substances in therapy," says Rolf Verres, medical director of the Department of Medical Psychology at the University of Heidelberg Hospital. "In Germany, there is simply a deficit in this respect."
Elsewhere, however, a comeback of hallucinogens in psychotherapy seems possible. In the United States, Britain, Israel and Switzerland, a number of studies have been recently approved involving the use of Ecstasy and psilocybin, an agent derived from hallucinogenic mushrooms. The goal of the research is to determine whether these substances can help in the treatment of traumatized war veterans and patients with anxiety disorders. Some of the researchers involved in the studies say that initial results are consistently encouraging.
But before Peter Gasser embarked on his study, no researcher had dared to use LSD, the strongest and most notorious of the hallucinogenic drugs. The outcome of his study will play a key role in determining how authorities handle similar applications in the future.
'I Am Not a Messiah'
Gasser, 49, ignored media inquiries from around the world for almost one-and-a-half years, so as not to jeopardize his sensitive experiment. Today, as he invites SPIEGEL to visit his practice for the first time, the first thing he does is to make one thing clear: "I am not a messiah, nor am I someone who aims to change society." He is interested exclusively in research, not creeping legalization of the drug, says Gasser, and he wants to demonstrate that LSD can play a positive role in psychotherapy.
Gasser is the president of the small Swiss Medical Society for Psycholytic Therapy, which advocates the therapeutic use of hallucinogens. The organization has about 50 members, of which about one-third are based in Germany. In the early 1990s, Gasser completed supplementary therapeutic training with psychedelic drugs, when it was still possible to do so in Switzerland with a special permit. He also tried LSD as part of the training.
The drug is chemically related to serotonin, a neurotransmitter produced naturally in the body. It affects the same regions of the brain, particularly the limbic system, where sensory input is filtered, processed and evaluated emotionally. LSD essentially disables the filtering function, so that the brain is flooded with information. It also elevates the release of the neurotransmitter dopamine in the so-called corpus striatum, further amplifying sensory overload.
As a result, the drug influences sensory perception, thought and moods. The sense of space and time changes, and the boundary between the self and the environment becomes blurred. This can be perceived as an exhilarating feeling of becoming one with the environment, or as a frightening loss of control over one's body and thoughts. Experts are unanimous in the view that LSD is not physically or emotionally addictive, however.
- Part 1: Swiss Psychiatrist Fights Fear with LSD
- Part 2: 'A Feeling of Mystical Oneness'
Stay informed with our free news services:
© SPIEGEL ONLINE 2009
All Rights Reserved
Reproduction only allowed with the permission of SPIEGELnet GmbH
Corriere della Sera
MORE FROM SPIEGEL INTERNATIONAL
German PoliticsMerkel's Moves: Power Struggles in Berlin
World War IITruth and Reconciliation: Why the War Still Haunts Europe
EnergyGreen Power: The Future of Energy
European UnionUnited Europe: A Continental Project
Climate ChangeGlobal Warming: Curbing Carbon Before It's Too Late